This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by NATARAJAN, R. Articles by NADLER, J. Search for Related Content PubMed PubMed Citation Articles by NATARAJAN, R. Articles by NADLER, J.

Role of the Lipoxygenase Pathway in Angiotensin II-Mediated Aldosterone Biosynthesis in Human Adrenal Glomerulosa Cells^*

R. NATARAJAN, N. STERN, W. HSUEH, Y. DO and J. NADLER

Los Angeles County/University of Southern California Medical Center, School of Medicine, Section of Endocrinology Los Angeles, California 90033
Sepulveda Veterans Administration Center, University of California-Los Angeles, San Fernando Valley Program (N.S.) Sepulveda, California 91343

Address requests for reprints to: Dr. Rama Natarajan, Los Angeles County/University of Southern California Medical Center, 1200 North State Street, Unit 1 18-632, Los Angeles, California 90033.

We studied the role of the lipoxygenase pathway of arachidonic acid metabolism in angiotensin II (All)-stimulated aldosterone secretion in normal and adenomatous human adrenal glomerulosa tissue. In freshly isolated normal adrenal glomerulosa cells, the All-mediated stimulation of aldosterone secretion was not altered by cyclooxygenase blockade with ibuprofen. In contrast, BW755c (10^–5 mol/L), a nonselective lipoxygenase inhibitor, and baicalein (10^–6 mol/L), a more selective 12-lipoxygenase blocker, inhibited All-mediated aldosterone secretion, but did not alter basal aldosterone secretion. The glomerulosa cells produced the lipoxygenase products 12- and 15- hydroxyeicosatetraenoic acid (HETE) in the basal state, as measured by high pressure liquid chromatography and RIA. However, All selectively stimulated only 12-HETE production [basal, 1329 ± 207 (±SE) pg (3.99 ± 0.62 pmol)/10⁵ cells·h; All, 2365 ± 333 (7.09 ± 1.0); n = 9; P < 0.02], suggesting that 12- lipoxygenase activation may be involved in All-mediated aldosterone secretion by normal cells. In addition, the lipoxygenase inhibitors that blocked All-mediated aldosterone secretion also prevented All-mediated 12-HETE formation. In contrast, neither ACTH nor K⁺ stimulated 12-HETE formation, suggesting that 12-lipoxygenase activation is primarily involved in All action in normal glomerulosa cells.

BW755c caused a marked dose-dependent inhibition of basal aldosterone secretion in freshly isolated cells from aldosteroneproducing adenomas [APA; basal, 66 ± 3 ng (182 ± 8 pmol)/10⁶ cells·h; 10^–5 mol/L BW755c, 49 ± 2 (136 ± 6); 10^–4 mol/L BW755c, 30 ± 2 (83 ± 6)]. In contrast, the cyclooxygenase inhibitor indomethacin and the selective 5-lipoxygenase inhibitor U60257 did not alter basal aldosterone secretion by these cells. The APA cells produced 12- and 15-HETE, and BW755c at the same dose that inhibited aldosterone secretion also inhibited the production of both 12- and 15-HETE. In the cultured APA cells, All-stimulated aldosterone secretion was inhibited by BW755c [basal, 26 ± 8 pg/mL (72.0 ± 22.1 pmol/L); All, 336 ± 79 (930 ± 218); All plus BW755c, 92 ± 38 (255 ± 105) n = 13; P < 0.01]. The lipoxygenase products 12- and 15-HETE restored the stimulatory effect of All during inhibition by BW755c, indicating a role for these lipoxygenase pathways in All-mediated aldosterone secretion in APA cells.

These results suggest that the stimulatory effects of AH on aldosterone secretion are mediated by stimulation of the lipoxygenase pathway in human zona glomerulosa cells.

^* This work was supported by a grant from the American Heart Association-Los Angeles Affiliate (841, GI), NIH Grants DK-39721 (to J.L.N.) and AM-30254 (to W.H.), and a Faculty Research and Innovation Award from the University of California (to J.L.N.). Presented in part at the 1987 Meeting of the American Federation for Clinical Research and published in abstract form only (Clin Res 35:400A, 1987).

Recipient of a Clinical Investigator Award from the NIH (HL-1496).

Received February 11, 1988.

This article has been cited by other articles:

				J. Gu, Y. Wen, A. Mison, and J. L. Nadler 12-Lipoxygenase Pathway Increases Aldosterone Production, 3',5'-Cyclic Adenosine Monophosphate Response Element-Binding Protein Phosphorylation, and p38 Mitogen-Activated Protein Kinase Activation in H295R Human Adrenocortical Cells Endocrinology, February 1, 2003; 144(2): 534 - 543. [Abstract] [Full Text] [PDF]

				I. Startchik, D. Morabito, U. Lang, and M. F. Rossier Control of Calcium Homeostasis by Angiotensin II in Adrenal Glomerulosa Cells through Activation of p38 MAPK J. Biol. Chem., June 28, 2002; 277(27): 24265 - 24273. [Abstract] [Full Text] [PDF]

				E. Middleton Jr., C. Kandaswami, and T. C. Theoharides The Effects of Plant Flavonoids on Mammalian Cells:Implications for Inflammation, Heart Disease, and Cancer Pharmacol. Rev., December 1, 2000; 52(4): 673 - 751. [Abstract] [Full Text] [PDF]

				H. Kawajiri, D. Zhuang, N. Qiao, T. Yoshimoto, M. Yamamoto, S. Iseki, and K. Hamaguchi Expression of Arachidonate 12-Lipoxygenase in Rat Tissues: A Possible Role in Glucagon Secretion J. Histochem. Cytochem., October 1, 2000; 48(10): 1411 - 1420. [Abstract] [Full Text]

				K. J. Scheidegger, S. Butler, and J. L. Witztum Angiotensin II Increases Macrophage-mediated Modification of Low Density Lipoprotein via a Lipoxygenase-dependent Pathway J. Biol. Chem., August 22, 1997; 272(34): 21609 - 21615. [Abstract] [Full Text] [PDF]

				J. A. Kim, J.-L. Gu, R. Natarajan, J. A. Berliner, and J. L. Nadler A Leukocyte Type of 12-Lipoxygenase Is Expressed in Human Vascular and Mononuclear Cells : Evidence for Upregulation by Angiotensin II Arterioscler Thromb Vasc Biol, July 1, 1995; 15(7): 942 - 948. [Abstract] [Full Text]